financetom
Business
financetom
/
Business
/
Teleflex Fiscal Q1 Earnings, Revenue Decline; Lowers 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Teleflex Fiscal Q1 Earnings, Revenue Decline; Lowers 2025 Guidance
May 25, 2025 11:21 PM

09:41 AM EDT, 05/01/2025 (MT Newswires) -- Teleflex ( TFX ) reported fiscal Q1 adjusted earnings Thursday of $2.91 per diluted share, compared with $3.21 a year earlier.

Analysts surveyed by FactSet expected $2.88.

Revenue for the quarter ended March 30 was $700.7 million, compared with $737.8 a year earlier. Analysts surveyed by FactSet expected $699.3 million.

Citing "currently enacted tariffs," the company lowered its guidance for fiscal year 2025 adjusted EPS to a range of $13.20 to $13.60 from previous guidance of $13.95 to $14.35. Analysts polled by FactSet expect $14.11.

Shares of Teleflex ( TFX ) fell by more than 4% in early trading.

Price: 137.05, Change: -1.17, Percent Change: -0.85

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alvotech, Partner Say European Medicines Agency Recommends Gobivaz Marketing Approval
Alvotech, Partner Say European Medicines Agency Recommends Gobivaz Marketing Approval
Sep 22, 2025
05:38 AM EDT, 09/22/2025 (MT Newswires) -- Alvotech ( ALVO ) and partner Advanz Pharma said Monday the European Medicines Agency's Committee for Medicinal Products for Human use adopted a positive opinion recommending approval for Gobivaz, the proposed biosimilar to Simponi, a biologic used to treat several chronic inflammatory diseases. Gobivaz continues to be under EMA regulatory review, with a...
Form 8.3 - Deliveroo PLC
Form 8.3 - Deliveroo PLC
Sep 22, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Sanofi Says FDA Extends Target Action Date of Tolebrutinib Application Review by 3 Months
Sanofi Says FDA Extends Target Action Date of Tolebrutinib Application Review by 3 Months
Sep 22, 2025
05:00 AM EDT, 09/22/2025 (MT Newswires) -- Sanofi ( SNY ) said Monday the US Food and Drug Administration has extended the target action date of its review of the new drug application of tolebrutinib to treat non-relapsing, secondary progressive multiple sclerosis by three months. The FDA determined that the additional information constituted a major amendment to the application, based...
BBVA Raises Offer for Banco Sabadell by 10% to $20 Billion
BBVA Raises Offer for Banco Sabadell by 10% to $20 Billion
Sep 22, 2025
05:37 AM EDT, 09/22/2025 (MT Newswires) -- Banco Bilbao Vizcaya Argentaria ( BBVA ) said Monday that it has raised its offer to acquire Banco Sabadell by 10% to 17 billion euros ($20 billion). Under the new bid, BBVA will offer one share for every 4.8376 Banco Sabadell shares, valuing Banco Sabadell shares at 3.39 euros apiece. The new offer...
Copyright 2023-2026 - www.financetom.com All Rights Reserved